Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply
CINCINNATI, April 27, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay. By eliminating this step, total assay cost is […]
Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020
CINCINNATI, April 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning […]
Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests
CINCINNATI, April 14, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19. Since the emergence of COVID-19 outbreaks in January, Meridian has supported molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 Molecular Diagnostics […]
MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH
CINCINNATI, April 02, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020. Preliminary Second Quarter Results The Company expects second quarter of fiscal 2020 revenues to be approximately […]
Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection. By utilizing Meridian’s specialized enzyme formulations (Fast RT-qPCR Mix and Lyo-Ready […]
Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA® assay. This analyzer and first assay play an important part in their initiative to maintain leadership in the gastrointestinal […]
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix. This specialized master mix offers a cost-effective and easier alternative to freeze-drying for ambient temperature stable real-time PCR assays. Meridian’s Air-Dryable qPCR Mix has […]
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million. The agreement […]
Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business; Positive customer feedback for our revogene™ […]
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started on the Chinese city of Wuhan, 56 people have already died and […]